Literature DB >> 15452374

Coexpression of Gas6/Axl in human ovarian cancers.

Wenshu Sun1, Jiro Fujimoto, Teruhiko Tamaya.   

Abstract

OBJECTIVES: Gas6, the protein product of the growth arrest-specific gene 6 (gas6), a member of the vitamin K-dependent protein family, was identified as a ligand for the Axl/Sky family of receptor tyrosine kinases. The aim is to study for the presence of Gas6 and its receptor Axl and Sky related to specific growth in the ovarian cancers, and to evaluate their plausible growth potential and mechanism.
METHODS: In ovarian cancers of 90 cases, the histoscores and mRNA levels of Gas6, Axl and Sky were determined by immunohistochemistry and competitive reverse transcription-polymerase chain reaction-Southern blot analysis using the recombinant RNA, respectively.
RESULTS: The histoscores and mRNA levels of Gas6 and Axl in ovarian cancers were significantly higher than in normal ovaries, regardless of histopathological type or clinical stage of ovarian cancers.
CONCLUSIONS: Gas6/Axl pathway could play a role in the complex events taking place during the early changes of ovarian cancer progression. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15452374     DOI: 10.1159/000079499

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  45 in total

1.  Structural basis for Gas6-Axl signalling.

Authors:  Takako Sasaki; Pjotr G Knyazev; Naomi J Clout; Yuri Cheburkin; Walter Göhring; Axel Ullrich; Rupert Timpl; Erhard Hohenester
Journal:  EMBO J       Date:  2005-12-15       Impact factor: 11.598

2.  GAS6 is an estrogen-inducible gene in mammary epithelial cells.

Authors:  Rigen Mo; Yiwei Tony Zhu; Zhongyi Zhang; Sambasiva M Rao; Yi-Jun Zhu
Journal:  Biochem Biophys Res Commun       Date:  2006-12-11       Impact factor: 3.575

3.  Axl gene knockdown inhibits the metastasis properties of hepatocellular carcinoma via PI3K/Akt-PAK1 signal pathway.

Authors:  Jingchao Xu; Li Jia; Hongye Ma; Yanping Li; Zhenhai Ma; Yongfu Zhao
Journal:  Tumour Biol       Date:  2013-12-18

Review 4.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

Review 5.  Vitamin K effects in human health: new insights beyond bone and cardiovascular health.

Authors:  Maria Fusaro; Maurizio Gallieni; Camillo Porta; Thomas L Nickolas; Pascale Khairallah
Journal:  J Nephrol       Date:  2019-12-19       Impact factor: 3.902

6.  Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.

Authors:  Ren Liu; Ming Gong; Xiuqing Li; Yue Zhou; Wenming Gao; Anil Tulpule; Preet M Chaudhary; Jae Jung; Parkash S Gill
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

7.  Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.

Authors:  Marguerite L Palisoul; Jeanne M Quinn; Emily Schepers; Ian S Hagemann; Lei Guo; Kelsey Reger; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2017-09-13       Impact factor: 6.261

8.  Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis.

Authors:  Hiroshi Honda; Fermin F Barrueto; Jean Gogusev; Dwight D Im; Patrice J Morin
Journal:  Reprod Biol Endocrinol       Date:  2008-12-02       Impact factor: 5.211

9.  Targeting TYRO3 inhibits epithelial-mesenchymal transition and increases drug sensitivity in colon cancer.

Authors:  C-W Chien; P-C Hou; H-C Wu; Y-L Chang; S-C Lin; S-C Lin; B-W Lin; J-C Lee; Y-J Chang; H S Sun; S-J Tsai
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

10.  Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.

Authors:  Anna Gustafsson; Anna-Karin Boström; Börje Ljungberg; Håkan Axelson; Björn Dahlbäck
Journal:  PLoS One       Date:  2009-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.